The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas: The Cumulative Multicenter European Experience
Open accessAbstract
OBJECTIVE: The objective of the study was to achieve limb salvage in patients with locally advanced soft tissue sarcomas that can only be treated by amputation or functionally mutilating surgery by performing an isolated limb perfusion (ILP) with tumor necrosis factor (TNF) + melphalan (M) as induction biochemotherapy to obtain local control and make limb-sparing surgery possible. SUMMARY BACKGROUND DATA: To increase the number of limb-sparing resections in the treatment of locally advanced extremity soft tissue sarcoma, preoperative radiation therapy or chemotherapy or a combination of the two often are applied. The ILP with cytostatic agents alone is another option but rarely is used because of rather poor results. The efficacy of the application of TNF in ILP markedly has changed this situation. METHODS: In 8 cancer centers, 186 patients were treated over a period of almost 4.5 years. There were 107 (57%) primary and 79 (43%) recurrent sarcomas, mostly high grade (110 grade III; 51 grade II; and 25 very large, recurrent, or multiple grade I sarcomas). The composition of this series of patients is unusual: 42 patients (23%) had multifocal primary or multiple recurrent tumors; median tumor size was very large (16 cm); 25 patients (13%) had known systemic metastases at the time of the ILP. Patients underwent a 90-minute ILP at 39 to 40 C with TNF + melphalan. The first 55 patients also received interferon-tau. A delayed marginal resection of the tumor remnant was done 2 to 4 months after ILP. RESULTS: A major tumor response was seen in 82% of the patients rendering these large sarcomas resectable in most cases. Clinical response rates were: 33 complete response (CR) (18%), 106 partial response (PR) (57%), 42 no change (NC) (22%), and 5 progressive disease (PD) (3%). Final outcome was defined by clinical and pathologic response: 54 CR (29%), 99 PR (53%), 29 NC (16%), and 4 PD (2%). At a median follow-up of almost 2 years (22 months; range, 6-58 months), limb salvage was achieved in 82%. Regional toxicity was limited and systemic toxicity minimal to moderate, easily managed, with no toxic deaths. CONCLUSIONS: In the setting of isolated limb perfusion, TNF is an active anticancer drug in patients. The ILP with TNF + melphalan can be performed safely in many centers and is an effective induction treatment with a high response rate that can achieve limb salvage in patients with locally advanced extremity soft tissue sarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Sugarman, B. J., Aggarwal, B. B., Hass, P. E., Figari, I. S., Palladino, M. A., & Shepard, H. M. (1985) · Science · doi:10.1126/science.3933111 · Cited by 1,580
Trojani, M., Contesso, G., Coindre, J. M., Rouesse, J., Bui, N. B., De Mascarel, A., Goussot, J. F., David, M., Bonichon, F., & Lagarde, C. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910330108 · Cited by 1,317
Boring, C. C., Squires, T. S., Tong, T., & Montgomery, S. (1994) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.44.1.7 · Cited by 1,315
Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., & Lejeune, F. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.52 · Cited by 719
Self-citationPhase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Eggermont, A. M., Schraffordt Koops, H., Liénard, D., Kroon, B. B., van Geel, A. N., Hoekstra, H. J., & Lejeune, F. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2653 · Cited by 398
Self-citationSpriggs, D. R., Sherman, M. L., Michie, H., Arthur, K. A., Imamura, K., Wilmore, D., Frei, E., & Kufe, D. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.13.1039 · Cited by 308
High-grade soft tissue sarcomas of the extremities
Potter, D. A., Kinsella, T., Glatstein, E., Wesley, R., White, D. E., Seipp, C. A., Chang, A. E., Lack, E. E., Costa, J., & Rosenberg, S. A. (1986) · Cancer · doi:10.1002/1097-0142(19860701)58:1<190::aid-cncr2820580133>3.0.co;2-5 · Cited by 282
Gaynor, J. J., Tan, C. C., Casper, E. S., Collin, C. F., Friedrich, C., Shiu, M., Hajdu, S. I., & Brennan, M. F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1317 · Cited by 268
Cited by
Hyperthermia in combined treatment of cancer
Wust, P., Hildebrandt, B., Sreenivasa, G., Rau, B., Gellermann, J., Riess, H., Felix, R., & Schlag, P. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00818-5 · Cited by 1,998
Self-citationTumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., & Corti, A. (2000) · Nature Biotechnology · doi:10.1038/81183 · Cited by 419
Metadata
- Authors
- Eggermont, A. M. M., Koops, H. S., Klausner, J. M., Kroon, B. B. R., Schlag, P. M., Liénard, D., van Geel, A. N., Hoekstra, H. J., Meller, I., Nieweg, O. E., Kettelhack, C., Ben-Ari, G., Pector, J.-C., & Lejeune, F. J.
- Venue
- Annals of Surgery
- Published
- 1996-12
- Volume
- 224
- Issue
- 6
- Pages
- 756-765
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2031539699
- Cited by
- 460
- References
- 17
- FWCI
- 24.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas: The Cumulative Multicenter European Experience. https://app.cochat.ai/papers/10.1097/00000658-199612000-00011
- The paper
- Eggermont, A. M. M., Koops, H. S., Klausner, J. M., Kroon, B. B. R., Schlag, P. M., Liénard, D., van Geel, A. N., Hoekstra, H. J., Meller, I., Nieweg, O. E., Kettelhack, C., Ben-Ari, G., Pector, J.-C., & Lejeune, F. J. (1996). Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas: The Cumulative Multicenter European Experience. Annals of Surgery. https://doi.org/10.1097/00000658-199612000-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.